This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/521719-india-covaxin-vaccine-covid19-trial/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| India’s indigenously developed Covaxin jab 78% effective against Covid-19 in trials, maker Bharat Biotech says | India’s indigenously developed Covaxin jab 78% effective against Covid-19 in trials, maker Bharat Biotech says |
| (2 months later) | |
| The Covid-19 vaccine developed by Indian pharmaceutical firm Bharat Biotech has been found to be 78% effective in preventing symptoms of Covid-19 and 100% against severe disease in stage three trials, the company said. | The Covid-19 vaccine developed by Indian pharmaceutical firm Bharat Biotech has been found to be 78% effective in preventing symptoms of Covid-19 and 100% against severe disease in stage three trials, the company said. |
| In a press release on Wednesday, Bharat Biotech published second-round interim results from stage-three trials of the country’s first indigenous Covid-19 jab. The data, which was based on a trial of more than 25,000 participants, showed the formulation to have 78% efficacy in preventing symptomatic Covid-19 – and totally effective in preventing severe forms of the disease. | In a press release on Wednesday, Bharat Biotech published second-round interim results from stage-three trials of the country’s first indigenous Covid-19 jab. The data, which was based on a trial of more than 25,000 participants, showed the formulation to have 78% efficacy in preventing symptomatic Covid-19 – and totally effective in preventing severe forms of the disease. |
| "The efficacy data against severe Covid-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively,” the company’s boss, Krishna Ella, said in a statement. | "The efficacy data against severe Covid-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively,” the company’s boss, Krishna Ella, said in a statement. |
| Balram Bhargava, secretary of health research & director general of the Indian Council of Medical Research, praised the hard work of the scientists involved and said he was pleased by the jab’s protection against new virus variants. | Balram Bhargava, secretary of health research & director general of the Indian Council of Medical Research, praised the hard work of the scientists involved and said he was pleased by the jab’s protection against new virus variants. |
| “I am also happy to note that Covaxin works well against most variants of SARS-CoV-2. These findings together consolidate the position of our indigenous vaccine in the global vaccine landscape,” he stated. | “I am also happy to note that Covaxin works well against most variants of SARS-CoV-2. These findings together consolidate the position of our indigenous vaccine in the global vaccine landscape,” he stated. |
| The vaccine has been administered several million times in India and has been given emergency approval in a number of other countries, including Iran, which granted a permit for its use in February, long before reflective trial results were available. Interim analysis from March 1 suggested the jab was 81% effective. | The vaccine has been administered several million times in India and has been given emergency approval in a number of other countries, including Iran, which granted a permit for its use in February, long before reflective trial results were available. Interim analysis from March 1 suggested the jab was 81% effective. |
| According to Bharat Biotech, more than 60 countries have expressed interest in purchasing the jab. Last week, India’s Ministry of Science & Technology said it was aiming at manufacturing 100 million doses every month by September, up from 10 million in April. | According to Bharat Biotech, more than 60 countries have expressed interest in purchasing the jab. Last week, India’s Ministry of Science & Technology said it was aiming at manufacturing 100 million doses every month by September, up from 10 million in April. |
| India is one of the world’s largest Covid-19 manufacturers, but has recently banned exports in an effort to prioritize the vaccination of its citizens amid a worrying increase in cases. The country’s latest mutant strain has also become an issue, with two major mutations potentially making it more resistant to vaccines and a ‘variant of concern’ across the world. | India is one of the world’s largest Covid-19 manufacturers, but has recently banned exports in an effort to prioritize the vaccination of its citizens amid a worrying increase in cases. The country’s latest mutant strain has also become an issue, with two major mutations potentially making it more resistant to vaccines and a ‘variant of concern’ across the world. |
| If you like this story, share it with a friend! | If you like this story, share it with a friend! |